Reevaluating thromboprophylaxis in COVID-19 outpatients: the case.... ISTH Academy. . Mar 1 2025; 4173994

(0)

You must be signed in to access your cart

Create Account Sign In

Home

not display
Featured
Webinars
Events
eLearning & CME
Topics
Industry portal
Journals
Open access
FXI Inhibitors

Search Loading

Navbar input

WAIT FOR SUGGESTIONS BY CATEGORY
OR CONTINUE TYPING IN YOUR KEYWORDS

ENTER ONE OR MULTIPLE KEYWORDS &
PRESS THE SEARCH BUTTON
From

To
Search

Favorites
Advanced Minimize

More ▾ Less ▸

Clear

Reevaluating thromboprophylaxis in COVID-19 outpatients: the case for a targeted, risk-based approach

Author(s):

Kaeshaelya Thiruchelvam

Kaeshaelya Thiruchelvam

Affiliations:
School of Pharmacy, International Medical University, Kuala Lumpur, Malaysia

Kaeshaelya Thiruchelvam, School of Pharmacy, International Medical University, 57000 Kuala Lumpur, Malaysia.

Syed Shahzad Hasan

Syed Shahzad Hasan

Affiliations:
School of Applied Sciences, University of Huddersfield, Huddersfield, United Kingdom

Dinesh Sangarran Ramachandram

Dinesh Sangarran Ramachandram

Affiliations:
School of Pharmacy, Monash University Malaysia, Bandar Sunway, Selangor, Malaysia

Chia Siang Kow

Chia Siang Kow

Affiliations:
School of Pharmacy, Faculty of Medical and Life Sciences, Sunway University, Bandar Sunway, Petaling Jaya, Malaysia

ISTH Academy. 03/01/25; 4173994

Dr.

All contributions

Biography

CLICK HERE TO LOGIN
REGULAR CONTENT

Login now to access Regular content available to all registered users.

Access to Premium content is currently a membership benefit.

Click here to join ISTH or renew your membership.

4173994

Discussion Forum (0)

Rate & Comment (0)

Code of conduct/disclaimer available in General Terms & Conditions

Trending Content

Rebalancing Therapies for Hemophilia: Are You Ready?

Shapiro A, Croteau S, Bisson E. Feb 26, 2025

Factor XI/XIa Inhibition as a Target for Anticoagulation: The What, Why, and How

Weitz J, Gailani D, Connors J. Sep 11, 2024

Factor XI/XIa Inhibition: Ensuring Safety and Efficacy

Weitz J, Al-Lamee R, Johnston C. Nov 12, 2024

Thromboprophylaxis in Pregnant Patients

Archibald W, Middeldorp S, Casais P. Mar 5, 2025

Treating ITP: Working Together to Improve Outcomes

Cooper N, Kuter D, Gernsheimer T. Nov 15, 2024

Anticoagulation in Patients with Chronic Kidney Disease

Tham D, Swan D, Kiskaddon A. Jan 29, 2025

Anticoagulation for stroke prevention in AFib and treatment of VTE and PVT in cirrhosis

Afzal A, Carlin S, Roberts L. Oct 15, 2024

Using AI to Predict or Guide Diagnosis/Treatment

Lam B, Sivapalaratnam S, Patell R. May 7, 2025

SSC on the Case: The Influence of Aging on von Willebrand Disease: Challenges and Considerations

Baker R, James P, Leebeek F, Connell N. Mar 20, 2025

Monitoring and Reversal for Factor Xa Inhibitors

Xu Y, Montalvao S, Campello E. Oct 30, 2024

Case Consult: Optimizing the Management of cTTP

Cataland S, Chaturvedi S, Scully M. Nov 19, 2024

Factor XI/XIa Inhibitors: Glossary of Terms

Presenters F. Feb 25, 2025

Advancing Care: Navigating the ISTH Hemophilia Clinical Practice Guidelines

DiMichele D, Rezende S, O'Connell N. Sep 5, 2024

Gene Therapy in Hemophilia: Clinical Care Strategies for Gene Therapy

Peyvandi F, La Mura V, Moro M. Oct 2, 2024

SSC on the Case: Platelet Immunology: Heavy Menstrual Bleeding in Patients with Immune Thrombocytopenia

Al-Samkari H, Nazy I, Lambert M, Sharma R. Apr 15, 2025

Long-term safety and effectiveness of emicizumab in people with hemophilia A in the Hemophilia Natural History...

Recht M. Jun 23, 2024

NXT007, a novel bispecific antibody, in FVIII chromogenic substrate assays

Kiialainen A. Jun 23, 2024

Long-term effectiveness and safety of emicizumab in people with hemophilia A in the Canadian Hemophilia Bleeding...

Poon M. Jun 23, 2024

Effectiveness of emicizumab under real-world conditions in patients of all ages with hemophilia A with and...

Oldenburg J. Jun 23, 2024

Comparison of FVIII and concizumab in thrombin generation assays under different conditions

Lund J. Jun 23, 2024

By clicking “Accept Terms & all Cookies” or by continuing to browse, you agree to the storing of third-party cookies on your device to enhance your user experience and agree to the user terms and conditions of this learning management system (LMS).
USER TERMS AND CONDITIONS | PRIVACY POLICY

Cookie Settings
Accept Terms & all Cookies

Anonymous User Privacy Preferences

Strictly Necessary Cookies (Always Active)

MULTILEARNING platforms and tools hereinafter referred as “MLG SOFTWARE” are provided to you as pure educational platforms/services requiring cookies to operate. In the case of the MLG SOFTWARE, cookies are essential for the Platform to function properly for the provision of education. If these cookies are disabled, a large subset of the functionality provided by the Platform will either be unavailable or cease to work as expected. The MLG SOFTWARE do not capture non-essential activities such as menu items and listings you click on or pages viewed.

Performance Cookies

Performance cookies are used to analyse how visitors use a website in order to provide a better user experience.

Google Analytics & Google Tag Manager embedded tracking functionalities

Google Analytics and Google Tag Manager embedded tracking functionalities are used for user behavior tracking/reporting. Google Analytics works in parallel and independently from MLG's features. Google Analytics relies on cookies and these cookies can be used by Google to track users across different platforms/services.